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Original Article   
Treatment Outcome of Multi-Drug Resistant Tuberculosis Treated As 
Outpatient in a Tertiary Care Center 
Zeeshan Waheed*, Muhammad Irfan, Ahmed Suleman Haque, Muhammad Owais Khan, Atif 
Zubairi, Noor ul Ain, Javaid A Khan 
 
ABSTRACT 
INTRODUCTION: Community-based out-patient treatment for multidrug-resistant 
tuberculosis (MDR TB) is relatively new concept with reported successful outcomes.  
OBJECTIVE:  To assess the treatment outcomes of HIV negative multidrug-resistant 
tuberculosis (MDR TB) patients treated as outpatient at a tertiary care center in Karachi, 
Pakistan.  
METHODS:  A retrospective observational study of 53 consecutive, culture proven HIV 
negative MDR TB patients (resistant at least to both Isoniazid (H) and Rifampin(R) 
treated at Aga Khan University Hospital, Karachi between August 1999 and March 
2007. Data were collected on predesigned performa regarding patient’s demography, 
clinical features, radiological findings, drug sensitivity, treatment and outcome.  
RESULTS:  A total of 53 HIV negative patients (27 males), with mean age of 37±15 
years (range 15-76 years), received treatment as outpatient for culture proven MDR TB. 
51 patients (96.2%) had pulmonary while 3 patients (5.6%) had extra-pulmonary TB. 
History of exposure to tuberculosis patients was found in 36 (67.9%) patients. 
Treatment regimen with 2nd line drugs was decided on individual basis according to DST 
on sputum culture results. The mean duration of treatment was 18 months. Successful 
outcome was seen in 25 patients (47.2%), 25 patients (47.2%) were loss to follow up 
and defaulted while 3 (5.6%) patients remain smear positive at the end of treatment. 
Success rate was 89 .2% in those who completed the treatment. 
CONCLUSION:  Community-based out-patient treatment strategy is both feasible and 
safe for the treatment of MDR-TB patients in resource limited country like Pakistan and 
this strategy should be integrated into the routine approach to treatment of MDR-TB 
patients in the country where the expertise are available. High default rate is this 
strategy is the main challenge which should be addressed. 
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Multi drug resistant Tuberculosis (MDR TB) is a growing problem around the world 
especially in countries where the prevalence of TB is high. Ever since the start of 
chemotherapy for tuberculosis, drug resistance has kept on increasing1. There are 
various different factors which play a role in the development of tuberculous drug 
resistance. Among them, the significant contributors include poor patient compliance, 
incorrect dosing and time duration of drug treatment2. Tuberculous organisms that 
achieve resistance preserve their infectivity better and have thus increased chances of 
survival3. MDR TB is more difficult to manage and costs more than its regular drug 
sensitive counterpart4.  
 
MDR-TB is an increasing health problem in Pakistan. According to World Health 
Organization (WHO) 5, the estimated cases of MDR tuberculosis in Pakistan are 3.4% 
and 36% in new and previously treated cases of tuberculosis respectively. Globally, 
Pakistan is ranked 8th in terms of estimated number of tuberculosis (TB) cases, with an 
incidence of 181/100,000 persons.5 
 
Treatment of MDR-TB is resource intensive and lasts for 24 months or more, requiring a 
combination of second-line drugs that are more expensive, less effective and more toxic 
than those used in standard first-line treatment regimens 6, 7. The cure including 
response rate of MDR-TB without human immunodeficiency virus (HIV) infection using 
individual tailored regimens was reported from 39% to 96 % in initially hospitalized 
patients.8-11 
The rationale for initial hospitalization has been to monitor complex drug regimens, 
optimize adherence and limit community transmission. However, there is no evidence 
that hospitalization actually limits community transmission.12  in fact the risk of 
nosocomial transmission, both to other patients and to health care workers becomes  
high.13-15 There are also economic and social costs involved in keeping patients isolated 
in hospitals, often far from home, and this can lead to default from treatment 
programmes.16 
 
Community-based treatment for MDR TB is not a new concept, and successful 
outcomes have been reported from Peru, 17 Korea 18 and Nepal.19 
 
The present study is a retrospective cohort analysis of individualized treatment 
outcomes of MDR TB cases treated in out-patient chest clinic at Aga Khan University 




This is an observational study which includes 53 consecutive patients of MDR T.B. All 
cases were culture proven and resistant at least to both Isoniazid (H) and Rifampin(R). 
All cases were HIV infection negative and treated at the outpatient chest clinic of Aga 
Khan University Hospital, Karachi between the duration of August 1999 and March 
2007. Data was collected on predesigned structured Performa regarding patient’s 
demography, clinical features, past medical history, radiological findings, drug 
sensitivity, Duration, type and effects of treatment and outcome.  
 
Drug susceptibility testing (DST) and drugs that had not been used in the past guided 
the therapy. The sputum cultures and susceptibility testing were done at Aga Khan 
Laboratory (AKL). AKL is the recognized laboratory for AFB culture in Pakistan. We 
administered minimum five drugs (range 5 to 7 drugs; median 5 drugs) during the 
intensive phase including one injectable aminoglycoside (mostly Kanamycin) and 
Quinolone (Ofloxacin and levofloxacin in most of the patients) from the 2nd line and also 
include the sensitive drug if any from the first line according to the sensitivity results on 
individual basis. During the continuation phase we used 3 to 4 oral drugs according to 
the sensitivity from the first and 2nd line drugs. In total, 20 tailored regimens with 
different drug combinations were prescribed according DST results.  
 
Patients were followed in outpatient chest clinic initially fortnightly during first month and 
then monthly. The patients were evaluated on each visit for clinical, microbiological and 
radiological response regularly. They were also evaluated for side effects of the 
medications. They were followed by sputum microscopy and chest X-ray every three-
month. Treatment was completed when the chemotherapy regimen had been taken for 
more than 18 months, usually 24 months for those who had attained negative sputum 
cultures toward the end of treatment.    
Outcome definitions 
We used the MDR TB treatment outcome definitions as follows: 
Successful outcome: Patient who completed treatment and consistently had negative 
smear Treatment default: Patients who did not receive treatment for  2 consecutive 
months were defined as having defaulted treatment.  
Treatment failure: Patients whose smear was positive at the end of six month or 
whose  
 2 smears were positive during final 12 months.  
Death: Patients who died due to any cause during treatment.  
Statistical analysis:  
The statistical package for social science SPSS (Release 16, standard version, 
copyright © SPSS) was used to analyze the data. The descriptive analysis was done for 
demographic, clinical and laboratory data. The results are presented as mean with 
standard deviation (SD) and numbers (percentages).  
RESULTS:  
A total of 53 HIV negative patients were treated for culture proven MDR TB as 
outpatient during study period out of which 27 (51.9%) patients were male and 26 
(49.1%) were female; with mean age of 37±15 years (range 15-76 years). Their base 
line characteristics are presented in Table I.  
Fifty one patients (96.2%) had pulmonary while 3 patients (5.6%) had extra-pulmonary 
TB. 5 (9.4%) had primary MDR TB while 48 (90.6%) had secondary MDR TB. History of 
exposure to tuberculosis patients was found in 36 (67.9%) patients.  37 (69.8%) patients 
had a history of taking two or more courses of antitubeculous treatment (ATT).  
All the patients were resistant to both Isoniazid (H) and Rifampicin (R). Resistance 
against Pyrazinamide (Z) was highest (77.4%) among the other first line drugs followed 
by ethambutol and streptomycin. Drug resistant pattern against the first and second line 
drugs are presented in Table II. Treatment regimen with 2nd line drugs was decided on 
individual basis according to DST and previous history of drugs usage. The mean 
duration of treatment was 18 months.  
Successful outcome was seen in 25 patients (47.2%). 25 patients (47.2%) were loss to 
follow up and defaulted. 3 (5.6%) patients remain smear positive at the end of 
treatment. No death occurs in patients who continue treatments and we do not know the 
outcome of defaulted patients.  Patients came to our clinic from all over the country as 
our hospital is the one of the best tertiary care hospital of the country. We tried to 
contact defaulted patients whom phone number was available. We were unsuccessful in 
most of the cases due either their phone number was incorrect or the patient 
deliberately did not attend the call. Due to non-availability of physical facilities for follow 
up of defaulted patients we could not traced the defaulters.  
Twenty eighty (52.8%) developed some side effects due to medications. They were 
mainly minor and managed accordingly. Among the minor side effects gastro-Intestinal 
symptoms (like nausea, vomiting, constipation) were the most common side effects 
seen in 22 patients (41.5%) followed by drug induced hepatitis, neuropathy, arthralgias 
and depression. 2 (3.8%) developed ototoxicity, 2 (3.8%) optic neuritis and 1(1.9%) 
developed  seizures that require discontinuation of responsible drugs.  
 
DISCUSSION:  
It is estimated 390 000–510 000 cases of MDRTB emerged globally (best estimate, 440 
000 cases).20 Pakistan ranks eighth among the list of 22 high TB burden countries with 
a TB related death rate of 43/100,000 population annually.21 The growth of the drug-
resistant TB epidemic in Pakistan is presented as challenges for the National 
Tuberculosis treatment Plan (NTP).  
 
In a developing country like Pakistan the infra structure of hospitals which is designed to 
deal with these drug-resistant TB patients is intended to deal with relatively small 
numbers of MDR cases thus  the need for consideration for the treatment of these MDR 
patients as out patients is stretched and Community-based treatment strategies have 
come into existence.  
 
Community-based treatment for drug-resistant TB is not a new concept, and successful 
outcomes have been reported elsewhere in the world17. There have been certain public-
private partnerships and non-governmental organizations that has developed 
community-based treatment projects in parts of Southern Africa. 22, 23 
 
The main opinion in favor of in-patient treatment for drug-resistant TB relate to the need 
to administer and monitor complex, toxic drug regimens and to limit the community 
spread of drug-resistant TB. However there is no proof that hospitalization actually limits 
community transmission and it is likely that most patients have been infectious for 
several months before hospitalization,12 Moreover, the risk of hospital acquired infection 
transmission, both to other patients and to health care workers, is also high.14,15 More 
importantly there are also economic and social costs involved in keeping patients 
isolated in hospitals, often away from their residence, and this can lead to default from 
treatment programs.16 and therefore there is a salient need to build up community-
based strategy for the treatment of drug resistant TB patients.24 
 
In our study successful outcome was seen in 25 patients i.e. around half of our study 
population 47.2% and only 3 (5.6%) patients remain smear positive at the end of 
treatment. These results support the evidence that it is feasible to develop a community 
based treatment program for the patients who had MDR- TB. The major drawback of 
this strategy found to be is the high defaulter rate although we could not identify the 
exact cause of the defaulters was not known but most likely is the lack of education and 
cost of medications are the major hindrance. If the above two major hurdles are 
overcome than these MDR-TB patients can be safely managed within the existing 
infrastructure of the TB program where the expertise is available on an out-patient 
basis. 
 
Regarding the side effects 52.8% developed some side effects due to medications but 
all are mainly minor in nature, they did not required to discontinue the therapy and are 
managed accordingly as out-patient. This again favors that hospitalization is not usually 
necessary for the management of the side effects. 25 
 
One interesting finding of our study is the presence of high resistance pattern of other 
first line drugs including Pyrazinamide (77.4%), Ethambutol (73.6%), and Streptomycin 
(69.4%). This is likely because of the fact that majority of our patient had got secondary 
MDR TB (90.6%) in which around one third (69.8%) had been treated with anti-
tuberculous drugs multiple times which is a risk factor for developing MDR TB. 
 
WHO recommends sequential sputum for AFB culture for the follow up of the MDR TB 
patients’ treatment, as cultures are more sensitive than AFB smear results but due to 
limited resources facility for sputum AFB culture was not available freely in our country 
and therefore the definition of the successful treatment is confined to smear results only. 
It is quite possible that our results of treatment success would have been lower if we 
had used the criteria of culture in follow up. Other limitations of the study includes; 
firstly; the study design i.e., a retrospective observational study involving individualized 
regimens, without any controls; secondly; the small number of patient population of the 
study as well. 
 
In conclusion, it is shown that a comprehensive outpatient therapeutic approach, the 
negative sputum conversion rate among MDR-TB patients who completed treatment 
was fairly high, despite of the limited resources. The results of the study here suggest 
that community-based treatment strategy is both feasible and safe in resource limited 
country and also that, this community based treatment strategy should be integrated 
into the routine approach to treatment of MDR-TB patients in the country where the 
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27  (50.9) 
26  (49.1) 
Age  
15 – 19 yrs 
20 – 39 yrs 
40 -  60 yrs 
>60 yrs 





Tobacco Usage 11 (20.8) 
H/O homelessness within 1 year prior to 
diagnosis of TB 
7  (13.2) 
Previous Exposure to TB patients 36  (67.9) 
Diabetes Mellitus 11  (20.8) 
Immunocompromised 3    (5.3) 
Steroid Use 2    (3.8) 





Numbers n (%) 
Rifampicin 53  (100) 
Isoniazid 53  (100) 
Pyrazinamide 41  (77.4) 
Ethambutol 5 micro gram 39  (73.6) 
Streptomycin 2/10 micro gram 37  (69.8) 
Ofloxacin 12  (22.6) 
Ethionamide 0   (0%) 
Capreomycin 1   (1.9) 
Cycloserine 6   (11.3) 
